On November 22, 2024, Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp, executed a sale of 22,000 shares of the company. Following this transaction, the insider now holds 22,951 shares of GeneDx Holdings Corp. The details of this transaction can be found in the SEC Filing.
GeneDx Holdings Corp (WGS, Financial) is a company engaged in providing genomic testing and information services. The company focuses on delivering diagnostic and clinical information to healthcare providers, enabling them to make informed decisions for patient care.
The insider transaction history for GeneDx Holdings Corp indicates a trend of more insider sells than buys over the past year. Specifically, there have been 5 insider buys and 44 insider sells during this period. Over the past year, Kevin Feeley has sold a total of 39,557 shares and has not made any purchases.
On the day of the recent sale, shares of GeneDx Holdings Corp were trading at $74.81, giving the stock a market cap of $2,210.349 million. The stock's GF Value is estimated at $12.67, resulting in a price-to-GF-Value ratio of 5.9. This suggests that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also incorporates a GuruFocus adjustment factor based on the company’s past returns and growth, along with future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
